APOE and Alzheimer disease: Further analysis showed an association between metformin use and faster decline in delayed memory among the APOE ε4 carriers, implying that the adverse interaction between metformin and APOE-ε4 genotype or AD pathology might neutralize the neuroprotective effect of metformin itself (Wu et al., 2020).